Journal article
Molecular Mechanisms Mediating Retinal Reactive Gliosis Following Bone Marrow Mesenchymal Stem Cell Transplantation
A Tassoni, A Gutteridge, AC Barber, A Osborne, KR Martin
Stem Cells | OXFORD UNIV PRESS | Published : 2015
DOI: 10.1002/stem.2095
Abstract
A variety of diseases lead to degeneration of retinal ganglion cells (RGCs) and their axons within the optic nerve resulting in loss of visual function. Although current therapies may delay RGC loss, they do not restore visual function or completely halt disease progression. Regenerative medicine has recently focused on stem cell therapy for both neuroprotective and regenerative purposes. However, significant problems remain to be addressed, such as the long-term impact of reactive gliosis occurring in the host retina in response to transplanted stem cells. The aim of this work was to investigate retinal glial responses to intravitreally transplanted bone marrow mesenchymal stem cells (BM-MS..
View full abstractGrants
Awarded by Fight for Sight
Funding Acknowledgements
This work was supported by funding from the Biotechnology and Biological Sciences Research Council (BBSRC), the HB Allen Charitable Trust, the Cambridge Eye Trust, the Jukes Glaucoma Research Fund, Pfizer, Neusentis and core support grant from the Wellcome Trust and MRC to the Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute. We thank Dr. Andras Lakatos from the University of Cambridge (U.K.) for donating the GFAP-STAT3-cKO mice, Verdon Taylor from the University of Basel (CH) for the Hes5 GFP<SUP>+ve</SUP> mice, Dr. Stefano Pluchino from the University of Cambridge (U.K.) for donating the mouse NPC line, and Astrid Limb from UCL, London (U.K.) for the MIO-M1 cell line.